ASORIN PM1: Glimepiride, Pioglitazone Hydrochloride & Metformin Hydrochloride SR Tablets
Composition – Glimepiride 1 mg + Pioglitazone 15 mg + Metformin Hydrochloride (Exteneded Release)
Description:
Asorin PM1 is bilayered tablet brings together three complementary antidiabetic agents—Glimepiride, Pioglitazone, and Metformin—for enhanced blood glucose control. Glimepiride, a sulfonylurea, promotes insulin release from pancreatic beta cells. Pioglitazone, a thiazolidinedione, reduces insulin resistance, improving glucose utilization in tissues. Metformin, a biguanide, decreases hepatic glucose production and enhances peripheral glucose uptake. The extended-release (SR) formulation of Metformin provides sustained glycemic control over the day, improving patient comfort and adherence.
Key Benefits:
✅Triple Mechanism of Action: Combines three powerful agents to target multiple pathways—pancreatic insulin secretion, peripheral insulin sensitivity, and hepatic glucose production—for comprehensive glycemic management.
✅Improved Insulin Sensitivity: Pioglitazone reduces insulin resistance, enhancing glucose uptake in muscle and fat tissues, especially beneficial in patients with high insulin resistance.
✅Dual-Phase Metformin Release: The sustained-release formulation of Metformin ensures prolonged blood glucose control, with fewer gastrointestinal side effects, improving patient adherence.
Targeted Specalists:
✅Endocrinologists
✅Internal Medicine Specialists
Disclaimer: To be administered only under the supervision of a qualified healthcare professional. Intended for use by registered medical practitioners. Not for public promotion.









